RT Journal Article
T1 Hepatitis C Virus Influences HIV-1 Viral Splicing in Coinfected Patients
A1 Martínez-Román, Paula
A1 López-Huertas, María Rosa
A1 Crespo Bermejo, Celia
A1 Arca Lafuente, Sonia
A1 Cortegano, Isabel
A1 Valle-Millares, Daniel
A1 Gaspar, María Luisa
A1 Martín-Carbonero, Luz
A1 Domínguez-Domínguez, Lourdes
A1 Ryan, Pablo
A1 de los Santos, Ignacio
A1 de la Fuente-Moral, Sara
A1 Fernández-Rodríguez, Amanda
A1 Coiras, Mayte
A1 Briz, Verónica
AB Coinfection with hepatitis C virus (HCV) influences HIV reservoir size. However, it is unknown whether this coinfection also induces a higher provirus transcription. Viral transcription is promoted by synergy between cellular factors such as NF-κB and the viral regulator Tat. The impact of HCV coinfection on HIV provirus transcription was analyzed in resting (r)CD4 T+ cells (CD3+CD4+CD25-CD69-HLADR-) and rCD4 T cells-depleted PBMCs (rCD4 T- PBMCs) from a multicenter cross-sectional study of 115 cART-treated HIV patients: 42 HIV+/HCV+ coinfected individuals (HIV+/HCV+), 34 HIV+ patients with HCV spontaneous clearance (HIV+/HCV−) and 39 HIV patients (HIV+). Viral transcription was assessed in total RNA through the quantification of unspliced, single spliced, and multiple spliced viral mRNAs by qPCR. Linear correlations between viral reservoir size and viral splicing were determined. A 3-fold increase of multiple spliced transcripts in rCD4 T+ cells of HIV+/HCV+ patients was found compared to HIV+ individuals (p < 0.05). As Tat is synthesized by multiple splicing, the levels of Tat were also quantified in these patients. Significant differences in single and multiple spliced transcripts were also observed in rCD4 T- PBMCs. Levels of multiple spliced mRNAs were increased in rCD4 T+ cells isolated from HIV+/HCV+ subjects, which could indicate a higher Tat activity in these cells despite their resting state.
PB MDPI
SN 2077-0383
YR 2020
FD 2020-07-03
LK https://hdl.handle.net/20.500.14352/8398
UL https://hdl.handle.net/20.500.14352/8398
LA eng
NO Ministerio de Economía y Competitividad (MINECO)
NO Instituto de Salud Carlos III (ISCIII)
NO Instituto de Salud Carlos III (ISCIII)/FEDER
DS Docta Complutense
RD 8 may 2024